Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029904 | 0.90 | OPRM1 (0.41) | OPRM1CRBNNEK2BACE1HTR2A | |
| SCHEMBL6614335 | 0.86 | OPRM1 (0.35) | OPRM1CRBNNEK2BACE1HTR2A | |
| SCHEMBL29749786 | 0.86 | HTR2A (0.42) | OPRM1CRBNBACE1HTR2A | |
| SCHEMBL11866693 | 0.76 | CRBN (0.36) | CRBN | |
| SCHEMBL6757690 | 0.76 | CRBN (0.36) | CRBN | |
| SCHEMBL6757693 | 0.76 | CRBN (0.36) | CRBN | |
| SCHEMBL1903325 | 0.75 | CRBN (0.33) | CRBN | |
| SCHEMBL29749693 | 0.75 | HTR2A (0.45) | OPRM1CRBNNEK2BACE1HTR2A | |
| SCHEMBL2169285 | 0.73 | CRBN (0.41) | CRBNNEK2 | |
| SCHEMBL22495622 | 0.71 | CRBN (0.39) | CRBNNEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453005-B2 | Inhibition of influenza M2 proton channel | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2086925-B1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288111-A1 | INHIBITION OF INFLUENZA M2 PROTON CHANNEL | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-11-24 | — | — | US | disclosed |
| US-8030518-B2 | E.g., N-(5-(4-fluorophenylamino)-1,3-dimethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3,3-dimethylbutanamide; treating or preventing neuropathic and chronic pain, bipolar disorder, migraine, epilepsy, a seizure or a disorder characterized by a seizure | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| EP-2086925-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | Valeant Pharmaceuticals International (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-2051966-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | Pfizer Products Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009007814-A1 | INHIBITORS OF CARBONIC ANHYDRASE | PFIZER INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008066900-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008017932-A2 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | PFIZER PRODUCTS INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234334-A1 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS | KCNB2, KCNB1, KCNA1 | OPRM1 1076/4885CRBN 3194/4885NEK2 1341/4885 |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | OPRM1 4177/4885CRBN 2172/4885NEK2 3184/4885 |
| US-20110288111-A1 | INHIBITION OF INFLUENZA M2 PROTON CHANNEL | HVCN1, TRPM2, ASIC1 | OPRM1 339/4885CRBN 4428/4885NEK2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.